Prognostic utility of pre‐biologic treatment correlates of childhood severe asthma exacerbation risk: Real world evidence
Beyond biologic treatment eligibility, using routinely collected clinical parameters to stratify pre-treatment SAE risk could improve prognostic accuracy and aid clinicians in tailoring therapy based on a patient's individual risk factors and likelihood of responding to a specific agent to maximize treatment effectiveness.
Authors
- Arthur H. Owora (ORCID: https://orcid.org/0000-0002-4580-7428)
- Erick Forno (ORCID: https://orcid.org/0000-0001-6497-9885)
- Benjamin M Gaston (ORCID: https://orcid.org/0000-0001-8794-1062)
- Yash Shah (ORCID: https://orcid.org/0009-0009-0272-8912)
- Bowen Jiang (ORCID: https://orcid.org/0000-0002-7386-290X)
Institutions
- Regenstrief Institute (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Pediatric Allergy and Immunology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/pai.70247
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00